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Background: Most natural host populations are exposed to a diversity of parasite communities and co-infection of
hosts by multiple parasites is commonplace across a diverse range of systems. Co-infection with Leishmania major
and Schistosoma mansoni may have important consequences for disease development, severity and transmission
dynamics. Pentavalent antimonials and Praziquantel (PZQ) have been relied upon as a first line of treatment for
Leishmania and Schistosoma infections respectively. However, it is not clear how combined therapy with the
standard drugs will affect the host and parasite burden in concomitance. The aim of the current study was to
determine the efficacy of combined chemotherapy using Pentostam and PZQ in BALB/c mice co-infected with L.
major and S. mansoni.
Methods: The study used BALB/c mice infected with L. major and S. mansoni. A 3 × 4 factorial design with three
parasite infection groups (Lm, Sm, Lm + Sm designated as groups infected with L. major, S. mansoni and L. major +
S. mansoni, respectively) and four treatment regimens [P, PZQ, P + PZQ and PBS designating Pentostam®
(GlaxoSmithKline UK), Praziquantel (Biltricide®, Bayer Ag. Leverkusen, Germany), Pentostam + Praziquantel and
Phosphate buffered saline] as factors was applied. In each treatment group, there were 10 mice. Lesion
development was monitored for 10 weeks. The parasite load, body weight, weight of the spleen and liver were
determined between week 8 and week 10.
Results: Chemotherapy using the first line of treatment for L. major and S. mansoni reduced the lesion size and
parasite loads but did not affect the growth response, spleen and liver. In the co-infected BALB/c mice, the use of
Pentostam or PZQ did not result in any appreciable disease management. However, treatment with P + PZQ
resulted in significantly (p < 0.05) larger reduction of lesions, net increase in the body weight, no changes in the
spleen and liver weight and reduced Leishman-Donovan Units (LDU) and worm counts than BALB/c mice treated
with Pentostam or PZQ alone.
Conclusions: The present study demonstrated that the combined first line of treatment is a more effective strategy
in managing co-infection of L. major and S. mansoni in BALB/c mice.
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Most natural host populations are exposed to a diverse
community of parasites, and with respect to epidemiologic
overlaps and human economic dynamics, comorbidity of
hosts by multiple parasites occurs across a diverse range
of systems [1-4]. Recent studies in vertebrates suggest that
interactions between co-infecting parasites have important
consequences for disease development, severity and trans-
mission dynamics [5,6]. Thus understanding the conse-
quences of co-infections in a host may be crucial for a
deeper understanding of the disease pathognomonic, epi-
demiology and effective disease control strategies.
In the developing world, leishmaniasis, caused by obli-
gate intracellular kinetoplastid protozoa of the genus
Leishmania, is endemic [7,8] and schistosomiasis, caused
by parasitic trematodes (schistosomes) have widely been
reported [9-13]. Leishmania and Schistosoma overlap
extensively in their epidemiological distributions and oc-
casionally co-infect the same individuals [14-21]. How
these two types of parasite might interact within co-
infected hosts and the associated epidemiology continues
to be debated. One line of argument indicates that the in-
teractions between the helminth and protozoan parasites
could affect both parties [22], while others argue that the
helminth/protozoan co-infection influences leishmaniasis
development without any effect on the helminth parasite
[23-25]. This bias may reflect the greater human disease
burden imposed by leishmaniasis compared to helminths
[26], as well as the ongoing need to understand what
causes variability in leishmaniasis infection outcomes.
Interactions among parasitic agents commonly alter
disease severity [1,27,28]. Co-infecting parasites may inter-
act either positively (facilitation) or negatively (competition)
via a range of mechanisms including resource competition,
immune-mediated interactions and direct interference. To
date, studies of helminth-protozoa co-infection have fo-
cused largely on immune-mediated mechanisms, no doubt
largely due to the known immunomodulatory effects of hel-
minths. Using the immune response mechanism, two major
pathways have been proposed by which helminths might
release parasites from immune pressure and thereby facili-
tate their replication, both of which involve the dampening
of pro-inflammatory immune responses [29-34]. Thus it
has been suggested that by polarizing immune responses
towards Th2-type effector mechanisms, helminths will
diminish the pro-inflammatory Th1-type mechanisms
needed to down modulate Leishmania in comorbidity.
These suggest that helminth co-infection might thus
impair the mechanisms necessary to control leishmania-
sis. The current immunomodulatory explanation is in
concurrence with observations in murine models, where
co-infection of L. major and S. mansoni exacerbated lesion
development compared to mice infected with L. major
alone [22-24,35]. The action of helminth infection affectingthe immune response of the host, may increase protozoan
multiplication substantially thus enhancing leishmaniasis
severity [23,24,26].
The chemotherapy of leishmaniasis is based on the use of
antimoniates, among which the most used are meglumine
antimoniate (Glucantime®) and sodium stibogluconate
(Pentostam®) [36-38]. The WHO recommended schisto-
somiasis control strategies for humans by focusing on the
large-scale population-based and repeated chemotherapy,
which is still the key strategy today. Three drugs have been
used, which differ in their effects on schistosome species:
metrifonate (targeting S. haematobium), oxamniquine
(targeting S. mansoni), and PZQ (for all human species)
[39,40]. Due to its broader spectrum, PZQ has finally be-
come the first-line medicine. Yet, advances in antiparasitic
chemotherapy have made combination chemotherapy a real
possibility [41,42]. Drug combinations aim to delay or pre-
vent the emergence of resistance, shorten the course of
treatment and lower required doses. Other potential ad-
vances include convenience, better compliance and lower
costs [43]. Nevertheless, the co-infection may potentially
affect the chemotherapy outcome using standard and/or
recommended drugs for single infections in the mice. As
yet, the pathognomonic and subsequent treatment of
protozoa and helminth concomitance in murine models is
not well understood. The aim of the current study was to
determine the efficacy of combined chemotherapy using
Pentostam® and Praziquantel in BALB/c mice co-infected
with L. major and S. mansoni. We hypothesize that treat-
ment of BALB/c mice co-infected with L. major and S.
mansoni using a combination of Pentostam and PZQ as
the first line treatments for L. major and S. mansoni re-




The study applied a 3 × 4 factorial design with three para-
site infection groups (Lm, Sm and Lm+ Sm designated as
groups infected with L. major, S. mansoni and L. major +
S. mansoni respectively) and four treatment regimens
[P, PZQ, P + PZQ and PBS designating Pentostam®
(GlaxoSmithKline, UK), Praziquantel(Biltricide®, Bayer
Ag. Leverkusen, Germany), Pentostam + Praziquntel
and Phosphate buffered saline] as factors. In each treat-
ment group, there were 10 mice. All treatments were
executed in triplicate.
Mice, parasites and experimental infections
Female (6–8 week old) BALB/c mice weighing 20 ± 2 g
were used in the experiment. The animals were obtained
from Kenya Medical Research Institute (KEMRI) animal
breeding facility, Nairobi-Kenya. The animals were moved
into the experimental room for acclimatization one week
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in 15 cm× 21 cm× 29 cm transparent plastic cages. They
were fed with pellets (Mice pellets UNGA® feeds) and
water ad libitum.
Kenya laboratory maintained (KEN-lab) strain of S.
mansoni parasite was used in the study. The isolate had
been routinely maintained in the laboratory at KEMRI
by passage in Biomphalaria pfeifferi snails and inbred
laboratory mice. For mouse infections, cercariae were
obtained from infected snails, counted and applied percu-
taneously by the ring method [44] to mice anesthetized
intraperitoneally with Pentobarbital sodium 80 mg/kg
(Rompun; Bayer Plc., Newbury, UK) [45]. For the S.
mansoni infection, mice were infected with 70 cercariae.
L. major (strain IDUB/KE/94 =NLB-144) was maintained
by serial passage in BALB/c mice to maintain virulence. An
aspirate isolate from the footpad of an infected BALB/c
mouse was cultivated in Schneider’s Drosophila insect
medium (Sigma, Saint Louis, USA), supplemented with
20% heat inactivated foetal bovine serum (FBS) (Cultilab,
Campinas, SP, Brazil), 500 μg/ml penicillin, 500 μg/ml
streptomycin and 250 μg/ml 5-fluorocytosine arabino-
side (all from Gibco, Grand Island, NY, USA) [46,47].
Promastigotes were incubated at 25°C and grown to sta-
tionary phase to generate infective metacyclic forms at 6th
day of culture. Promastigotes in the medium were counted
with a hemocytometer (Improved Double Neubauer)
(Pharmacia-GE Healthcare, Uppsala, Sweden) with a
Nikon optiphot optical microscope at 40× magnification.
Mice were inoculated with 1 × 106 stationary phase L.
major promastigotes in 50 μl PBS into the Left Hind Foot-
pad (LHFP) using a 29 gauge needle.
Treatment
At the 5th week post infection (day 29), each of the para-
site infection groups, were either treated with Pentostam
(P), Praziquantel (PZQ), P + PZQ or PBS for the controls.
20 mg/kg bodyweight/day standard dose of Pentostam
(GlaxoSmithKline, UK), was prepared and administered
intraperitoneally (ip) for 28 days [48]. Praziquantel
(Biltricide®, Bayer Ag. Leverkusen, Germany) was sus-
pended in PBS and was administered to the mice by
gavage at a total dosage of 600 mg/kg body weight (di-
vided into 2 equal doses of 300 mg/kg) given 8 hours
apart [49,50].
Sampling, lesion measurement and determination of
parasite burden
A total of five mice were sampled at week 8 and week
10 for analysis of L. major parasite loads and S. mansoni
worm counts. Lesion sizes of L. major infected mice,
which was defined as the difference in thickness be-
tween the infected footpad and the non-infected contra-
lateral footpad, was monitored weekly by measurementusing a Starret dial caliper (Mitutoyo, Suzano, SP, Brazil)
[24,51]. The weight of the mice was also monitored on a
weekly basis.
S. mansoni worms were recovered by portal perfusion
[52], with perfusion buffer [phosphate buffered saline,
0.02 μl/ml heparin (monoparin; CP Pharmaceuticals
Ltd.,Wrexham, UK)]. The worms were washed free of
erythrocytes and counted using a dissecting microscope.
The percentage worm recovery and percentage worm re-
duction was calculated [50] as shown below:
%worm recovery
¼Mean of total worms in Experimental group
Mean of worms in infected control
 100
%worm reduction ¼
Mean of worms in Infected Control‐
Mean of worms in Experimental group
Mean of worms in infected control
 100
The liver and spleen were removed and weighed and
changes post-infection and chemotherapy were deter-
mined based on percentage reduction/increase, spleeno-
somatic and hepato-somatic indices [50]. Splenic L.
major burdens were determined from Giemsa-stained
impression smears and expressed as Leishman-Donovan
units (the number of amastigotes per 1000 host nuclei,
multiplied by the weight of the organ) [53-55].
Ethical clearance
All procedures were approved by the ethics committees
for animal care and research: KEMRI Animal Care and
Use Committee (ACUC), Scientific Steering Committee
(SSC) and Ethical Review Committee (ERC). The guide-
lines were strictly adhered to during the research.
Statistical analysis
All statistical analyses were performed with a version of
STATISTICA 10.0 statistical packages. Normality of data
distributions were checked by means of the kurtosis to
determine any need for applying appropriate data trans-
formation procedures [55]. For each parameter analyzed,
differences among treatment groups exposed to different
drugs were tested by Factorial ANOVA. Comparison of ef-
ficacies among different treatment groups and time was
carried out using factorial repeated measure ANOVA.
Differences on L. major parasites and S. mansoni worm
counts were analyzed using Friedman’s Two-Way
ANOVA as count data take discreet variables. Percentage
data were arcsine transformed before subjecting the data
to statistical analysis of Variance. In cases where signifi-
cant differences were discerned means were compared
using Tukey’s HSD test [56]. All analyzed results were de-
clared significant at p < 0.05.
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The lesion sizes of BALB/c mice at the start of infection,
at treatment and response after treatment with Pentostam,
PZQ and combination of P + PZQ between week 8 and 10
is shown in Figure 1. During the first five weeks, there was
a progressive increase of lesion size in BALB/c mice indi-
cating progression of disease infection. There were signifi-
cant differences in lesion sizes among different treatments
(F = 21.1223, p = 0.0001) between week 5 to week 10. The
largest reduction in lesion size after five weeks post
infection followed by chemotherapy was observed in L.
major infected BALB/c mice treated with Pentostam.
Nevertheless, there was no (p > 0.05) difference in lesion
size of L. major infected BALB/c mice treated with either
Pentostam or with a combination of P + PZQ. In the co-
infected BALB/c mice, treatment with P + PZQ resulted in
significantly (p < 0.05) the largest reduction of lesion when
compared with BALB/c mice treated with Pentostam or
PZQ alone. PZQ had no effect on L. major infected
BALB/c mice.
Body weights, weights of spleen and weights of the
liver of BALB/c mice infected with L. major, S. mansoni






















1 L. major P
2 L. major P
3 L. major P
4 L. major P
5 L. major + S. mansoni P
6 L. major + S. mansoni P
7 L. major + S. mansoni P
8 L. major + S. mansoni P
Figure 1 Lesion sizes of BALB/c mice at the start of infection, during
Pentostam and PZQ for 10 weeks.presented in Table 1. There were significant differences
in the body weights, weight of spleen and in the weight
of liver of BALB/c mice under different treatments
between the eighth and tenth week (p < 0.05). The lar-
gest increase in body weight occurred in mice infected
with L. major and treated with Pentostam, in S. mansoni
infected mice and treated with PZQ; nonetheless, com-
bined therapy resulted in net increase in body weights of
BALB/c mice singly infected with either L. major and S.
mansoni. Treatment of L. major and S. mansoni co-
infected BALB/c mice through monotherapy (either
Pentostam or PZQ) resulted in reduced body weights
while using combination therapy of P + PZQ resulted in a
net increase in the body weight between week 8 and 10. It
was observed that the largest increase in the weight of the
spleen was in control groups. As for the infected and
treated mice, in the L. major or S. mansoni infected mice,
treatment with Pentostam and PZQ respectively, resulted
in a slight and non-significant (p > 0.05) increase in the
weight of spleen between weeks 8 and 10. Simultaneous
chemotherapy for either infection did not show any ap-
preciable change in the weight of spleen. However, the


















the start of treatment with Pentostam, PZQ and combination of
Table 1 Mean (± SEM) body weight, weight of spleen and weight of the liver of BALB/c mice infected with L. major, S.
mansoni and those co-infected with L. major + S. mansoni
Parasite
infection
Body weights (g) Weight of spleen (g) Weight of the liver (g)
Treatments Week 8 Week 10 % change Week 8 Week 10 % change Week 8 Week 10 % change
L. major P 18.2 ± 0.8 20.4 ± 1.4 12.1 0.14 ± 0.007 0.15 ± 0.012 7.14 0.81 ± 0.091 0.80 ± 0.084 −1.26
PZQ 18.0 ± 0.5 16.6 ± 1.4 −7.77 0.20 ± 0.027 0.24 ± 0.009 20.00 0.84 ± 0.014 0.86 ± 0.025 2.13
P + PZQ 18.6 ± 0.5 20.2 ± 1.2 8.60 0.15 ± 0.005 0.15 ± 0.007 0.00 0.79 ± 0.015 0.77 ± 0.014 −1.50
PBS 18.4 ± 0.4 14.4 ± 1.1 −21.7 0.19 ± 0.027 0.24 ± 0.008 26.32 0.84 ± 0.011 0.86 ± 0.014 2.15
S. mansoni P 18.0 ± 0.6 16.1 ± 1.1 −10.6 0.20 ± 0.010 0.24 ± 0.009 20.00 1.59 ± 0.023 1.64 ± 0.012 3.14
PZQ 18.0 ± 0.6 19.8 ± 0.9 10.0 0.17 ± 0.022 0.19 ± 0.011 11.76 0.83 ± 0.006 0.82 ± 0.004 −1.26
P + PZQ 18.6 ± 0.8 20.3 ± 0.6 9.10 0.16 ± 0.006 0.16 ± 0.005 0.00 0.83 ± 0.013 0.82 ± 0.049 −1.38
PBS 18.4 ± 0.9 14.5 ± 1.7 −21.2 0.20 ± 0.025 0.25 ± 0.006 25.00 1.08 ± 0.011 1.11 ± 0.009 2.77
L. major + S.
mansoni
P 19.8 ± 0.2 18.2 ± 0.5 −8.08 0.22 ± 0.006 0.25 ± 0.013 13.60 1.55 ± 0.041 1.58 ± 0.032 3.20
PZQ 18.4 ± 0.3 17.0 ± 0.8 −7.60 0.22 ± 0.009 0.24 ± 0.007 9.09 1.59 ± 0.012 1.61 ± 0.011 1.95
P + PZQ 18.4 ± 0.6 19.8 ± 0.4 7.60 0.19 ± 0.016 0.20 ± 0.012 5.26 0.82 ± 0.012 0.83 ± 0.013 1.22
PBS 17.9 ± 0.9 14.4 ± 1.5 −19.6 0.21 ± 0.007 0.27 ± 0.018 28.57 1.04 ± 0.014 1.08 ± 0.017 4.24
ANOVA Main effect
F 19.311 7.421 9.241 8.421 7.112 14.0214
p value 0.0000 0.0005 0.0001 0.0004 0.0071 0.0000
Repeated
measure
F 9.2114 7.5515 5.5544
p value 0.0007 0.0021 0.0081
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BALB/c infected with S. mansoni and treated with
Pentostam. In the co-infected mice, treatment with
Pentostam or PZQ alone resulted in a significant (p < 0.05)
increase in the weight of spleen between weeks 8 and 10.
On the contrary, treatment of BALB/c co-infected with L.
major + S. mansoni with P + PZQ resulted in slight but
non-significant (p > 0.05) increase in weight of the spleen.
Treatment of BALB/c mice infected with L. major or S.
mansoni with Pentostam and PZQ respectively or a com-
bination of P + PZQ resulted in a slight reduction in the
weight of the liver. There were opposing trends in the
weight of the liver when treatment of L. major or S.
mansoni infection was conducted using PZQ and
Pentostam respectively. In mice, co-infected with L.
major + S. mansoni there were significant (p < 0.05) in-
creases in the weight of the liver when Pentostam and
PZQ were used as respective chemotherapeutants.
Nevertheless, in co-infected mice, treatment with com-
bined therapy of P + PZQ resulted in a slight but non-
significant (p > 0.05) increase in the liver weight. All the
controls resulted in significant (p < 0.05) increases in
weight of the liver.
The spleeno-somatic and hepato-somatic indices of
BALB/c infected mice under different treatments are
shown Table 2. The spleeno-somatic index and hepato-
somatic index of L. major infected BALB/c mice reducedsignificantly (p < 0.05) between week 8 and week 10 when
treatment was carried out using Pentostam and P + PZQ
but increased with treatment using PZQ. In BALB/c mice
infected with S. mansoni, treatment with Pentostam
resulted in a significant (p < 0.05) increase of spleeno-
somatic and hepato-somatic indices. Meanwhile treatment
of S. mansoni infected BALB/c mice with PZQ resulted in
a non-significant (p > 0.05) increase in the spleeno-somatic
index but significantly reduced the hepato-somatic index.
Combined therapy of P + PZQ significantly (p < 0.05) re-
duced the spleeno-somatic and hepato-somatic indices. In
co-infected BALB/c mice, treatment with either Pentostam
or PZQ resulted in a significant (p < 0.05) increase in both
the spleeno-somatic and hepato-somatic indices. However,
when treatment was done using combined therapy of P +
PZQ, the spleeno-somatic index decreased slightly but
with a larger significant (p < 0.05) reduction observed in
hepato-somatic index. Regardless of the parasitic levels
of infection of the BALB/c mice, all mice maintained in
the control groups had increased spleeno-somatic and
hepato-somatic index between week 8 and 10.
In L. major infected BALB/c mice, treatment with
Pentostam and P + PZQ resulted in the lowest LDU,
which significantly (p < 0.05) reduced between week 8
and week 10 (Figure 2). In the PZQ treated and control
groups, there was a significant increase in the LDU be-
tween week 8 and week 10. In BALB/c mice co-infected
Table 2 The spleeno-somatic and hepato-somatic indices of BALB/c infected with L. major, S. mansoni and those co-
infected with L. major + S. mansoni undergoing various treatments with Pentostam and PZQ between week 8 and
week 10
Infection Drug administration Spleeno-somatic index Hepato-somatic index
L. major Week 8 Week 10 Week 8 Week 10
P 0.77 ± 0.031 0.74 ± 0.039 4.45 ± 0.14 3.92 ± 0.08
PZQ 1.11 ± 0.173 1.45 ± 0.100 4.67 ± 0.15 5.18 ± 0.23
P + PZQ 0.81 ± 0.016 0.74 ± 0.029 4.25 ± 0.18 3.81 ± 0.13
PBS 1.03 ± 0.150 1.67 ± 0.084 4.57 ± 0.10 5.97 ± 0.32
S. mansoni P 1.11 ± 0.088 1.49 ± 0.066 8.83 ± 1.11 10.19 ± 0.50
PZQ 0.94 ± 0.073 0.96 ± 0.064 4.61 ± 0.09 4.14 ± 0.21
P + PZQ 0.86 ± 0.081 0.79 ± 0.044 4.46 ± 0.07 4.04 ± 0.22
PBS 1.09 ± 0.081 1.72 ± 0.073 5.87 ± 1.12 7.66 ± 0.27
L. major+ P 1.11 ± 0.165 1.37 ± 0.076 7.83 ± 1.44 8.68 ± 2.04
S. mansoni PZQ 1.20 ± 0.111 1.41 ± 0.077 8.64 ± 0.12 9.47 ± 0.13
P + PZQ 1.03 ± 0.075 1.01 ± 0.041 4.46 ± 0.11 4.19 ± 0.07
PBS 1.17 ± 0.046 1.88 ± 0.051 5.81 ± 0.16 7.50 ± 0.43
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duced LDU significantly (p < 0.05). In the rest of the
treatments there were significant (p < 0.05) increase in
LDU over the two weeks time.
Trends in the worm counts between S. mansoni infected
and those co-infected with L. major + S. mansoni were
similar (Table 3). In the Pentostam treated and control
groups, there was a significant (p < 0.05) increase in the
worm counts between week 8 and week 10. In S. mansoni
infected BALB/c mice, treatment with PZQ and P + PZQ

















Figure 2 The LDU of L. major parasite in BALB/c mice infected with L.
receiving various treatments of Pentostam and PZQ between week 8mansoni co-infected BALB/c mice, treatment with P +
PZQ resulted in a significant (p < 0.05) reduction in worm
counts as compared to mice treated with PZQ alone.
In the S. mansoni and L. major + S. mansoni infected
BALB/c mice, there was a significant (p < 0.05) reduction
in the% worm recovery when PZQ and P + PZQ was ap-
plied in managing the infection albeit there was no sig-
nificant (p > 0.05) difference observed when Pentostam
was used (Figure 3a). Subsequently, % worm reduction
increased when PZQ and P + PZQ was administered in
the treatment (Figure 3b).P PZQ P + PZQ PBS
L. major + S. mansoni 
atments
k 10
major and those co-infected with L. major and S. mansoni
and week 10.
Table 3 Worm counts of BALB/c infected with S. mansoni
and those co-infected with L. major + S. mansoni under
various treatments with Pentostam and PZQ between
week 8 and week 10
Infection Drug administration Week 8 Week 10
S. mansoni P 34.80 ± 6.09 41.2 ± 2.58
PZQ 10.4 ± 1.29 8.4 ± 1.50
P + PZQ 14.4 ± 1.24 11.60 ± 1.24
PBS 36.20 ± 5.17 46 ± 2.79
L. major + S. mansoni P 30.60 ± 7.59 38.6 ± 2.68
PZQ 11.40 ± 2.74 8.80 ± 1.44
P + PZQ 7.40 ± 2.60 5.0 ± 1.20
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Figure 3 Worm recovery and reduction in BALB/c mice infected
with S. mansoni and those co-infected with L. major and S.
mansoni under different treatments. Symbol †, †† and †††
significant differences in worm reduction/recovery at ∝ = 0.05, 0.01
and 0.001 respectively using Tukey’s HSD Test. NS denotes no
significant differences among treatments.
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The drugs recommended in the management of Leish-
mania are pentavalent antimonials such as Pentostam,
while management of Schistosoma is done using PZQ.
Yet, the interactions among parasitic agents in the hosts
may alter the epidemiology, development and severity of
the disease [1] with unknown consequences on the
efficacy of the combined first line treatments. The aim
of the present study was to evaluate the efficacy of com-
bined first line of treatment in managing co-infection of
L. major and S. mansoni in BALB/c mice. There was no
evidence of antagonistic effects of PZQ on Pentostam, or
a possible additive and/or synergistic effect on Pentostam
during Leishmania mono-infection treatment, which may
be associated with PZQ and Pentostam distinct targets
and mode of action [36-40,57,58]. Studies in murine
models indicate concurrent infection of L. major and S.
mansoni, exacerbate lesion size and/or inability to resolve
footpad lesions as rapidly as mice infected with L. major
which correlates with the impaired ability to rescind para-
sitic burden [22]. Therefore, it is apparent that a strategy
to enhance the resolution of infection in mice is through
targeting the S. mansoni. In this study, when we applied
combined chemotherapeutics of first line treatment for S.
mansoni (PZQ) and L. major (Pentostam) comorbidity,
there were large reductions of lesion size in the mice com-
pared to the reduction in lesion size in BALB/c treated
with Pentostam or PZQ alone. This observation reveals
that through action on S. mansoni, the Pentostam acts
much faster to heal the lesion in BALB/c mice. Previously,
pre-infection with S. mansoni delayed the resolution of L.major lesions while L. major infection had no impact on
the course of S. mansoni infection in co-infected mice
[24]. Since the granuloma response by S. mansoni forms a
discrete niche that facilitates the intracellular survival of
Leishmania [26], the reduction of S. mansoni through the
first line of treatment could enhance the healing response
in co-infected mice. It is also probable that healing in
combined therapy treatment was achieved through
immune response pathways [39,57-60]. Nonetheless, the
co-infected BALB/c mice under mono-therapy with
Pentostam had significantly smaller lesion nodules as
compared to the PZQ treated mice that had no significant
difference between the start of treatment and after treat-
ment. Although subject to further scrutiny, it would be
possible that the divergence would be explained by having
the two arms of immunity operational at the same time.
Treatment of S. mansoni infection using PZQ has been
demonstrated to result in better Th2 responses thus limit-
ing Th1 responses, which tend to abrogate Leishmania in-
fection [24,25,34,39,40,58,61-63].
Co-infection may cause an increased stress response in
mice manifested through reduced physiological func-
tioning and resulting in reduced growth response [64].
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in the current study. The largest increase in body weight
occurred in mice infected with L. major and treated with
Pentostam, and in S. mansoni infected mice and treated
with PZQ, suggesting efficacy of the first line treatments
against mono-parasite infections as previously deter-
mined [48,50,60-63]. However, the lower percentage in-
crease in body weight of the L. major infected mice after
treatment with P + PZQ suggest a more pathological
response of BALB/c mice to one of the drugs indicating
that combined therapy may tend to be more toxic to
mice infected by one parasite than single therapy ad-
ministration. Although pathological effects of combined
Pentostam and PZQ has rarely been shown in co-
infected mice, we observed that between week five and
six there were signs of toxicity [65] in BALB/c mice co-
infected with L. major and S. mansoni and subjected to
concurrent treatment with P + PZQ. In the co-infected
mice, the use of combined therapy was found to result
in a slight increase in the body weight, which may be
concomitant to normal somatic growth. The reduced
body weights in BALB/c mice co-infected with L. major
and S. mansoni and treated with either Pentostam or
PZQ therapies alone suggest that elimination of one para-
site by the single drug does not preclude the pathological
impacts of the other parasites resulting in physiological
impairment of the mice and hence the observed reduced
body weight.
Higher splenomegaly has been previously associated
with high parasite burden in co-infected conspecifics
[22]. Naturally therefore, the elimination of the parasite
tends to reverse the condition. The reduction in the
weight of spleen in BALB/c infected with L. major and S.
mansoni and treated with Pentostam and PZQ respect-
ively confirm the efficacy of the first line treatment drugs
on these two parasites, which appeared to reduce spleno-
megaly. However, the non-significant increase in the
weight of the spleen between week 8 to 10 suggested effi-
cacious control of the parasites and the increased weight
of the spleen was a response to normal somatic growth.
In diverse pathogenesis and pathology findings, infec-
tion with the parasitic helminth S. mansoni is predomin-
antly associated with liver enlargement resulting in
hepatomegaly, which although less severe, has been shown
in the presence of L. major infection in murine models
and hence possible aggravated hepatomegaly in concomi-
tance of the two parasitic diseases [22,66-70]. In the
present study, chemotherapy with first line treatments for
L. major or S. mansoni single infection reduced the liver
weights between week 8 and 10 suggesting reduced inci-
dence of hepatomegaly which concurs with previous find-
ings [50,71]. The increased liver weight suggests higher
incidences of hepatomegaly in the co-infected mice when
monotherapy was used as treatment modality. Indicatingthat modulation of hepatomegaly requires the elimination
of both parasites from the BALB/c mice. We confirmed in
the present study that when combined therapy of P +
PZQ was applied during co-infection, there were non-
significant increases in the liver weights between week 8
and 10 pointing to elimination of the parasites that may
cause hepatomegaly.
The study also established that in BALB/c mice co-
infected with L. major + S. mansoni, there was a signifi-
cant reduction in LDU and S. mansoni worm counts be-
tween week 8 and 10 when treatment was carried out
using P + PZQ. The results concur with previous find-
ings that demonstrated respective chemotherapy for the
helminth or protozoan parasites at curative doses effect-
ively reducing parasitic loads; even in the absence of total
elimination of the parasites at curative or subcurative dos-
ages particularly in parasitic helminth infection, the need
for repeated chemotherapy to attain optimal therapy is
considered to be core [41,49,50,69,72-74]. However, when
combination therapy was used during the co-infection,
signs of toxicity were noted at the start of the treatment,
perhaps due to accumulation of the drugs in the tissues,
particularly in liver and spleen and associated Pentostam
reversible cardio toxicity among other side effects of PZQ
and Pentostam previously reported [37-40,75]. The reduc-
tion of parasitic load in the current study in the combined
therapy may reflect the mode of action of the drugs.
Pentostam acts upon several targets that include influen-
cing the bioenergetics of Leishmania parasite by inhibiting
parasite glycolysis, fatty acid beta-oxidation and inhibition
of ADP phosphorylation [36,37,57]. Praziquantel produces
a well-documented effect on intracellular Ca2+ levels in
adult schistosomes; within 5 minutes of exposure to the
drug, adult schistosomes exhibit a rapid sustained con-
traction of the worm’s musculature and vacuolization and
disruption of the parasite tegument, an effect associated
with the subsequent exposure of parasite antigens on the
surface of the worm [58].
For a long time, treatment of parasite infections in
murine models has focused on the single therapy treat-
ments which use first line treatment that is generally
acceptable. Recent cases of increased incidences of
polyparasitism in vertebrates call for better ways to man-
age co-infections. These not withstanding, interactions
between co-infecting parasites that have pronounced
consequences for disease development, severity and trans-
mission dynamics may complicate the management of
concomitance. The results of the present study demon-
strate that the use of combined therapy resulted in man-
agement of Leishmania and Schistosoma in BALB/c mice.
Conclusions
In the present study, treatment of BALB/c mice co-
infected with L. major and S. mansoni was achieved
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of Pentostam and Praziquantel, representing the first line
treatments of Leishmania and Schistosoma respectively.
Combined therapy resulted in reduced lesion size, low
parasite burden and appeared to have fewer effects on
the physiology of the BALB/c mice. Although most of
the parasitic infections are managed as single infections,
the problem of co-infection among patients is increas-
ingly being recognized. The results obtained demon-
strate that management of co-infections can be achieved
by appropriate application of combined therapy of first
line treatment, which will go a long way in the manage-
ment of some of the most neglected tropical diseases.
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